Cellares
Develops automated cell therapy manufacturing platforms
$257MSeries D
Role not disclosedDF
Duquesne Family Office
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Industrial tech · Jan 1, 2026
Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.
Recorded funding activity
Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $257M 1 disclosed · full round size, not this investor’s share